The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
Open accessAbstract
BACKGROUND & AIMS: Interactions between C-C chemokine receptor types 2 (CCR2) and 5 (CCR5) and their ligands, including CCL2 and CCL5, mediate fibrogenesis by promoting monocyte/macrophage recruitment and tissue infiltration, as well as hepatic stellate cell activation. Cenicriviroc (CVC) is an oral, dual CCR2/CCR5 antagonist with nanomolar potency against both receptors. CVC's anti-inflammatory and antifibrotic effects were evaluated in a range of preclinical models of inflammation and fibrosis. METHODS: Monocyte/macrophage recruitment was assessed in vivo in a mouse model of thioglycollate-induced peritonitis. CCL2-induced chemotaxis was evaluated ex vivo on mouse monocytes. CVC's antifibrotic effects were evaluated in a thioacetamide-induced rat model of liver fibrosis and mouse models of diet-induced non-alcoholic steatohepatitis (NASH) and renal fibrosis. Study assessments included body and liver/kidney weight, liver function test, liver/kidney morphology and collagen deposition, fibrogenic gene and protein expression, and pharmacokinetic analyses. RESULTS: CVC significantly reduced monocyte/macrophage recruitment in vivo at doses ≥20 mg/kg/day (p < 0.05). At these doses, CVC showed antifibrotic effects, with significant reductions in collagen deposition (p < 0.05), and collagen type 1 protein and mRNA expression across the three animal models of fibrosis. In the NASH model, CVC significantly reduced the non-alcoholic fatty liver disease activity score (p < 0.05 vs. controls). CVC treatment had no notable effect on body or liver/kidney weight. CONCLUSIONS: CVC displayed potent anti-inflammatory and antifibrotic activity in a range of animal fibrosis models, supporting human testing for fibrotic diseases. Further experimental studies are needed to clarify the underlying mechanisms of CVC's antifibrotic effects. A Phase 2b study in adults with NASH and liver fibrosis is fully enrolled (CENTAUR Study 652-2-203; NCT02217475).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 CVC Effect on Monocyte/Macrophage Migration. (A) Monocyte/macrophage recruitment reduced in TG-induced mouse model of peritonitis after pre-treatment with CVC (PO BID or QD dosing); (B) cenicriviroc (1 μM) inhibits CCL2-mediated chemotaxis of activated murine macrophages (F4/80+/CD11b+) ex vivo. *p < 0.05 vs. TG + vehicle control; **p < 0.01 vs. TG + vehicle control; ***p < 0.001 vs. TG + vehicle control; † p < 0.001 vs. TG + DEX; ‡ p = 0.018 vs. vehicle control. aVehicle control: 0.5% [w/v] methylcellulose + 1% Tween®-80 (pH ~1.3). BID, twice daily; CCL2, C-C chemokine ligand 2; CVC, cenicriviroc; CVC5, CVC 5 mg/kg/day; CVC20, CVC 20 mg/kg/day; CVC100, CVC 100 mg/kg/day; DEX, dexamethasone; PO, oral gavage; QD, once daily; SEM, standard error of the mean; TG, thioglycollate.](https://figures.cochat.ai/paper-figures/dfdd355eafec4c6e9c04f1a46b1d736c/antifibrotic-effects-of-the-dual-ccr2-ccr5-antagonist-cenicriviroc-in-animal-figure-1.jpg)
![Fig 2 Reduction of Plasma ALT Levels in NASH Model. *p < 0.05 vs. vehicle control. aVehicle control: 0.5% [w/v] methylcellulose + 1% Tween®-80 (pH ~1.3). ALT, alanine aminotransferase; BID, twice daily; CVC, cenicriviroc; CVC20, CVC 20 mg/kg/day; CVC100, CVC 100 mg/kg/day; NASH, non-alcoholic steatohepatitis; SD, standard deviation.](https://figures.cochat.ai/paper-figures/1a6e539bef254c4eae8e1034fb2ebd96/antifibrotic-effects-of-the-dual-ccr2-ccr5-antagonist-cenicriviroc-in-animal-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These preclinical studies demonstrated a significant reduction in collagen deposition (148).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [148]
In the citing paper
“Pharmacological inhibition of CCL2 by mNOX-E36 (121) or the use of cenicriviroc, a CCR2/CCR5 antagonist, gave promising anti-inflammatory and antifibrogenic results in mouse models (122).”
From Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy (2024) · doi:10.1146/annurev-pharmtox-020524-012013 · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“The NAS, a histological tool developed to assess disease severity in humans, was assessed in a blinded fashion and calculated according to Kleiner’s criteria on H&E-stained sections [38].”
MethodChronic kidney disease: global dimension and perspectives
Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. Y.-M., & Yang, C.-W. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60687-x · Cited by 4,383 · cited 1×
“Likewise, renal fibrosis is a common manifestation of chronic kidney disease [3], associated with elevated risks of morbidity and mortality [4].”
BackgroundPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“Pioglitazone, obeticholic acid and elafibranor have shown amelioration of insulin resistance and/ or antifibrotic activity in animal models [53–55] and have undergone Phase 2 clinical evaluation [50,51,56] (NCT01694849).”
BackgroundNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · cited 1×
“Pioglitazone, obeticholic acid and elafibranor have shown amelioration of insulin resistance and/ or antifibrotic activity in animal models [53–55] and have undergone Phase 2 clinical evaluation [50,51,56] (NCT01694849).”
BackgroundNonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061 · cited 1×
“transforming growth factor-beta [TGF-beta]), produced by activated macrophages, promote transdifferentiation of HSCs into myofibroblasts, which are the primary source of scarforming matrix proteins, including fibrillary collagen types 1 and 3, and the contractile protein alpha-smooth muscle actin (alpha-SMA) [1,6–8].”
BackgroundRatziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Pathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894 · cited 2×
“Fibrosis results from a sustained inflammatory response to chronic organ injury and is characterized by the deposition of extracellular matrix proteins, including collagen types 1 and 3 [1].”
BackgroundSelf-citationRoles for chemokines in liver disease
Marra, F., & Tacke, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.043 · Cited by 829 · cited 1×
“CCR2 and CCR5 have become attractive targets for antifibrotic therapy, as interactions with their ligands, including CCL2 and CCL5, mediate recruitment of inflammatory cells to the site of liver injury, and contribute to fibrosis [9–15,40].”
BackgroundPradere, J.-P., Kluwe, J., De Minicis, S., Jiao, J.-J., Gwak, G.-Y., Dapito, D. H., Jang, M.-K., Guenther, N. D., Mederacke, I., Friedman, R., et al. (2013) · Hepatology · doi:10.1002/hep.26429 · Cited by 613 · cited 1×
“transforming growth factor-beta [TGF-beta]), produced by activated macrophages, promote transdifferentiation of HSCs into myofibroblasts, which are the primary source of scarforming matrix proteins, including fibrillary collagen types 1 and 3, and the contractile protein alpha-smooth muscle actin (alpha-SMA) [1,6–8].”
Background
Research works printed but not linked: 3
- Jalbert E, Byron MM, Shikuma C, Jenkins H, Lefebvre E, Barbour JD. Cenicriviroc achieves high CCR5 receptor occupancy at low nanomolar concentrations. Presented at: 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014); 2014 Mar 3; Boston, MA, USA. 530.
- MM Byron, 2015, Dual CCR2/CCR5 antagonism by cenicriviroc efficiently inhibits both MCP-1 and RANTES induced chemokine receptor internalization in murine pro-inflammatory monocytes, J Immunol, 194, 187, 10.4049/jimmunol.194.Supp.187.8 · DOI
- M Thompson, 2014, Improvements in APRI and FIB-4 fibrosis scores correlate with decreases in sCD14 in HIV-1 infected adults receiving cenicriviroc over 48 weeks, Hepatology, 60, 424A
Cited by
Items 201–300 of 326
Cenicriviroc, a CCR2/CCR5 antagonist, promotes the generation of type 1 regulatory T cells
Madan, U., Verma, B., & Awasthi, A. (2024) · European Journal of Immunology · doi:10.1002/eji.202350847 · Cited by 19
“Cenicriviroc has also been investigated for the potential treat-ment of non-alcoholic steatohepatitis (NASH) [21–24], by targeting CCR2 and CCR5 expressing monocytes, tissue-resident macrophages (Kupffer cells), and hepatic stellate cells (HSC) and inhibiting their fibrogenetic functions.”
BackgroundRapacciuolo, P., Finamore, C., Giorgio, C. D., Fiorillo, B., Massa, C., Urbani, G., Marchianò, S., Bordoni, M., Cassiano, C., Morretta, E., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01651 · Cited by 17
Pérez‐Martínez, L., Ochoa‐Callejero, L., Rubio-Mediavilla, S., Narro-Íñiguez, J., Bernardo, I., Oteo, J. A., & Blanco, J. R. (2018) · Translational research · doi:10.1016/j.trsl.2018.01.004 · Cited by 17
Sumida, Y., Yoneda, M., Toyoda, H., Yasuda, S., Tada, T., Hayashi, H., Nishigaki, Y., Suzuki, Y., Naiki, T., Morishita, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144939 · Cited by 16
Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis
Gudd, C. L. C., Atkinson, S. R., Mitchell, E., Mawhin, M., Turajlic, S., Larkin, J., Thursz, M. R., Goldin, R. D., Powell, N., Antoniades, C. G., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008078 · Cited by 16
Geervliet, E., Karkdijk, E., & Bansal, R. (2024) · Scientific Reports · doi:10.1038/s41598-024-67926-6 · Cited by 15
The effect of liver disease on hepatic microenvironment and implications for immune therapy
Brown, Z. J., Ruff, S. M., & Pawlik, T. M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1225821 · Cited by 20
“the CCL2/CCR2 axis impaired macrophage recruitment to the liver and reduced hepatosteatosis, inflammation, and fibrosis (Baeck et al., 2012; Lefebvre et al., 2016).”
BackgroundEmerging pharmacologic therapies for primary sclerosing cholangitis
Cheung, A., Lazaridis, K. N., LaRusso, N. F., & Gores, G. J. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000352 · Cited by 17
Xia, Y., Lei, C., Yang, D., & Luo, H. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107369 · Cited by 16
The Role of Mesenchymal Stromal Cells in Tissue Repair and Fibrosis
Akasaka, Y. (2021) · Advances in Wound Care · doi:10.1089/wound.2021.0037 · Cited by 17
Recent updates on targeting the molecular mediators of NAFLD
Wang, J., Wang, L., Zhang, X., Zhang, P., Cai, J., She, Z., & Li, H. (2023) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02282-4 · Cited by 15
“CVC has been studied in extensive preclinical studies for the treatment of NASH and fibrosis, and the findings provide a solid theoretical basis for longer-term clinical studies [121, 122].”
BackgroundUpdate on Clinical Trials for Nonalcoholic Steatohepatitis.
Nathani, R. R., & Bansal, M. B. (2023) · PubMed Central · Cited by 20
Liver Macrophage Diversity in Health and Disease
Horn, P., & Tacke, F. (2024) · Results and problems in cell differentiation · doi:10.1007/978-3-031-65944-7_7 · Cited by 17
Wang, Z., Park, H., & Bae, E. J. (2019) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2019.23.6.459 · Cited by 14
Lei, M., & Chen, G. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.05.011 · Cited by 12
Zhang, W., Shao, T., Wang, C., Wang, S., & An, L. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2613502 · Cited by 15
“Beyond immunosuppressants, the dual CCR2/CCR5 inhibitor Cenicriviroc reduces pro-inflammatory macrophage recruitment and exhibits anti-fibrotic effects in liver fibrosis animal models [124,125].”
Evolving paradigm of treatment for autoimmune hepatitis
Czaja, A. J. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1319764 · Cited by 12
“(monocytes and monocyte-derived macrophages) in an animal model of acetaminophen toxicity [177], decreased collagen deposition in three animal models of liver fibrosis [155], and been well tolerated in patients with mild-to-moderate hepatic impairment [178].”
BackgroundAmano, Y., Tsuchiya, S., Imai, M., Tohyama, K., Matsukawa, J., Isono, O., Yasuno, H., Enya, K., Koumura, E., & Nagabukuro, H. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.055 · Cited by 14
Thapa, K., Grewal, A. S., Kanojia, N., Rani, L., Sharma, N., & Singh, S. (2020) · Current Drug Discovery Technologies · doi:10.2174/1570163817666200121143959 · Cited by 14
Kjær, M. B., George, J., Kazankov, K., & Grønbæk, H. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1817740 · Cited by 14
Kartasheva-Ebertz, D., Gaston, J., Lair-Mehiri, L., Massault, P. P., Scatton, O., Vaillant, J., Va, M., Pol, S., & Lagaye, S. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i2.187 · Cited by 15
How effective are nonalcoholic fatty liver disease models for drug discovery?
Hundertmark, J., & Tacke, F. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1776258 · Cited by 13
Chemokine receptors in COVID-19 infection
Gutierrez-Chavez, C., Aperrigue-Lira, S., Ortiz-Saavedra, B., & Paz, I. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.05.002 · Cited by 11
Bowler, S. A., Siriwardhana, C., Mitchell, B. L., D’Antoni, M. L., Ogata-Arakaki, D., Souza, S. A., Yee, R. K., Gangcuangco, L. M. A., Chow, D. C., Ndhlovu, L. C., et al. (2019) · HIV Research & Clinical Practice · doi:10.1080/25787489.2020.1719319 · Cited by 11
Alteration in immune function in patients with fatty liver disease
Gregory, S. N., Perati, S. R., & Brown, Z. J. (2022) · Hepatoma Research · doi:10.20517/2394-5079.2022.34 · Cited by 12
Liu, Y., Cong, K., Li, Q., Zhang, D., & Sheng, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1741398 · Cited by 14
Chandrasekaran, P., & Weiskirchen, R. (2023) · Livers · doi:10.3390/livers4010001 · Cited by 10
“A phase 3 RCT (NCT03028740 AURORA) was initiated to evaluate the effects of 150 mg/day CVC with long-term follow-up over a 5-year period [54].”
Novel biomarkers in patients with uncontrolled hypertension with and without kidney damage
Brobak, K. M., Halvorsen, L. V., Aass, H. C. D., Søraas, C. L., Aune, A., Olsen, E., Bergland, O. U., Rognstad, S., Blom, K. B., Birkeland, J. A. K., et al. (2024) · Blood Pressure · doi:10.1080/08037051.2024.2323980 · Cited by 11
“However, conflicting results exist regarding RANTES’ role in generating renal fibrosis [51,52].”
Zhang, R., Zhong, B., He, J., Yang, X., He, M., Zeng, W., Pan, J., Fang, Z., Jia, J., & Liu, H. (2022) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2022.104811 · Cited by 10
Macrophage malfunction in Triptolide-induced indirect hepatotoxicity
Qin, T., Hasnat, M., Zhou, Y., Yuan, Z., & Zhang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.981996 · Cited by 11
“NASH, liver fibrosis, HIV, and liver cancer (Marra and Tacke, 2014; Stutchfield et al., 2015; Lefebvre et al., 2016; Tacke, 2017; Challa et al., 2019).”
BackgroundZhu, S., Wu, Z., Wang, W., Wei, L., & Zhou, H. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02216-y · Cited by 12
Ozkan, H., Francesco, M. D., Willcockson, H. H., Valdés‐Fernández, J., Francesco, V. D., Granero‐Moltó, F., Prósper, F., Decuzzi, P., & Longobardi, L. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01235-1 · Cited by 10
“Different molecules have been developed to target either the receptor (monoclonal antibody MC-21 [24] and small molecules such as RS504393 and cenicriviroc [7, 8, 25]) or the ligand (NoxE36) in different pathologies [26, 27].”
BackgroundChen, G., Yu, Y., Zhu, Y., Nagashimada, M., Wang, Y., Nagata, N., & Xu, L. (2024) · Endocrinology · doi:10.1210/endocr/bqae069 · Cited by 12
Myeloid cell path to malignancy: insights into liver cancer
Ramirez, C. F. A., & Akkari, L. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.02.006 · Cited by 11
Moragrega, Á. B., Gruevska, A., Fuster‐Martínez, I., Benedicto, A. M., Tosca-Cuquerella, J., Montón, C., Víctor, V. M., Esplugues, J. V., Blas‐García, A., & Apostolova, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115537 · Cited by 11
Finotti, M., Romano, M., Auricchio, P., Scopelliti, M., Brizzolari, M., Grossi, U., Piccino, M., Benvenuti, S., Morana, G., Cillo, U., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060499 · Cited by 9
“The inhibition of these receptors could lead to a reduction in liver inflammation and fibrosis [98,99].”
BackgroundMacrophage heterogeneity in liver fibrosis
Wang, W., Li, S., Liu, Y., Ding, X., Yang, Y., Chen, S., Cao, J., Tacke, F., Dong, W., & Lan, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639455 · Cited by 8
Sharma, S. K., Ghufran, S. M., Aftab, M., Bihari, C., Ghose, S., & Biswas, S. (2024) · Journal of Cell Communication and Signaling · doi:10.1002/ccs3.12015 · Cited by 9
“24 YM155 treatment decreases both M1 and M2 ‐ polarized macrophage accumulation at the injury site of the fibrotic liver.”
BackgroundUpdate on the role of Chemokines and Chemokine Receptors in Liver Fibrosis
Li, H. (2023) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-4660 · Cited by 10
“Cenicriviroc (CVC), an oral, dual CCR2/CCR5 antagonist, causes anti-inflammatory and antifibrotic effects by reducing monocyte/macrophage recruitment and collagen deposit [42, 59-62].”
BackgroundInfluentialAsgharpour, A., Dinani, A. M., & Friedman, S. L. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2020.01.04 · Cited by 10
“Additionally, there was less collagen deposition in the liver in both CVC treatment groups compared to control with a lower NAS in both treatment groups compared to control (78).”
Self-citationThe therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis
Doulberis, M., Papadimitriou, K., Papaefthymiou, A., Kountouras, J., & Pοlyzos, S. A. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00012 · Cited by 8
“Cenicriviroc (CVC), a dual CCR type 2 and type 5 antagonist, has been gaining increasing interest, owing to its anti-inflammatory and anti-fibrotic properties shown in animal models [9, 10].”
BackgroundInfluentialZivko, C., Witt, F., Koeberle, A., Fuhrmann, G., & Luciani, P. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.11.025 · Cited by 8
“Cenicriviroc has been emerging as a candidate drug for patients with NASH, due to its dual antagonism of the chemokine receptors CCR2 and CCR5 (involved in monocyte chemotactic recruitment) [14 – 16].”
Macrophages protect against sensory axon degeneration in diabetic neuropathyPreprint
Hakim, S., Jain, A., Petrova, V., Indajang, J., Kawaguchi, R., Wang, Q., Duran, E. S., Nelson, D., Adamson, S. S., Greene, C. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.30.577801 · Cited by 8
“Mice treated with CVC starting after 8 weeks on the diet (Fig.”
MethodInfluentialMacrophage ontogeny and functional diversity in cardiometabolic diseases
Gautier, E. L., Askia, H., Murcy, F., & Yvan‐Charvet, L. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.06.023 · Cited by 9
Chatterjee, T., & Zarjou, A. (2025) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2024.12.004 · Cited by 7
Role of cenicriviroc in the management of nonalcoholic fatty liver disease
Neokosmidis, G., & Τζιόμαλος, Κ. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i48.5415 · Cited by 6
Lee, Y. A., & Friedman, S. L. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch36 · Cited by 7
Self-citationWang, Z., Liang, G., Peng, J., Gu, Y., Zhang, X., Ding, C., Yu, T., & Li, Z. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.12.006 · Cited by 6
Bhattacharjee, J., Beaton, G., Ravula, S. B., Lee, S. J., Bacon, K. B., Jenkinson, C. P., Warren, M., Tucci, F. C., & Kohli, R. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000323 · Cited by 6
“…researchers have tried NASH remission approaches targeting various receptors of molecular signaling pathways, including bile acid receptors, [3] peroxisome proliferator – activated receptors, [4] liver-specific thyroid hormone receptors, [5] chemokine receptors, [ 6 ] and hepatic lipid metabolism.”
BackgroundPharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis
Esteban, J. P., & Asgharpour, A. (2020) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.10.003 · Cited by 5
Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma
Akl, M. G., & Widenmaier, S. B. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1089124 · Cited by 9
“Cenicriviroc is a dual CCR2/CCR5 antagonist that has been investigated extensively in preclinical models of NASH and shown to diminish liver macrophage infiltration, inflammation, and fibrosis (Lefebvre et al., 2016; Krenkel et al., 2018), which is consistent with the effect of deleting CCR2 (Miura et al.”
BackgroundGrzych, G., Bernard, L., Lestrelin, R., Tailleux, A., & Staels, B. (2022) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2022.09.005 · Cited by 6
Chen, Y., Jia, B., Tong, X., Yin, S., Ni, W., Zhao, Q., Shi, J., & Li, J. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000864 · Cited by 6
Exploring the potential of drug repurposing for liver diseases: A comprehensive study
Ali, F. E. M., Abdel‐Reheim, M. A., Hassanein, E. H. M., El‐Aziz, M. K. A., Althagafy, H. S., & Badran, K. S. A. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122642 · Cited by 7
Steiner, C. A., & Higgins, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-90578-5_23 · Cited by 6
Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease
Cho, Y. E., Kwon, Y. S., & Hwang, S. (2022) · Liver Research · doi:10.1016/j.livres.2022.06.001 · Cited by 7
Palmer, M., Arman, A. C., Lawitz, E., Sanchez, W. E., Mittal, S., Hassanein, T., Hansen, S. G., Meidling, J., Cunningham, B., Buss, N., et al. (2025) · Liver international communications. · doi:10.1002/lci2.70028 · Cited by 4
“Extended receptor occupancy and enhanced specificity compared to small molecules, as determined by the CCR5 receptor occupancy assay, support sustained therapeutic effects over time, which are required for a chronic disease, such as MASH [31–34].”
Huang, G., & Li, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1751290 · Cited by 5
“…through specific targets, such as anti-CD163-dexamethasone conjugated drugs that can precisely deliver drugs to macrophages, alleviating liver inflammation and fibrosis (156, 157); CCR2/CCR5 antagonist cenicriviroc delays disease progression by inhibiting monocyte recruitment to the liver (158).”
In vivo diffuse reflectance spectroscopic analysis of fatty liver with inflammation in mice
Takihata, Y., Kawauchi, S., Ogata, S., Nishidate, I., Sato, S., Yamamoto, J., & Kishi, Y. (2021) · Surgery Open Science · doi:10.1016/j.sopen.2021.07.002 · Cited by 3
Hepatic macrophage mediated immune response in liver steatosis driven carcinogenesis
Tu, T., Alba, M. M., Datta, A. A., Hong, H., Hua, B., Jia, Y., Khan, J., Nguyen, P., Niu, X., Pammidimukkala, P., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.958696 · Cited by 3
“Treatment with a dual antagonist for CCR2 and CCR5, receptors for CCL2 and CCL5, significantly reduced macrophages and protected rats from liver injury in a diet induced NASH model (79) and has shown promising effects FIGURE 2”
BackgroundKe, F., Wu, X., Zheng, J., & Li, C. (2023) · Drug Development Research · doi:10.1002/ddr.22062 · Cited by 3
Current and Emerging Treatments for Non-alcoholic Steatohepatitis
Horn, C. L., Ta, A. C., & Gunn, N. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00540-y · Cited by 3
Jia, J., Yuan, G., Wang, Z., Xia, Y., Pan, Y., Zhang, L. R., Tang, F., Yu, X., Yang, Z., Wang, D., et al. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666221208105720 · Cited by 4
Targeting macrophages in liver fibrosis
González del Barrio, L., Ipsen, D. H., Pfister, D. R., Hancz, D., & Scott, C. L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1835489 · Cited by 3
Role of CCL8 in cancer immunity and tumor progression: Implications for cancer treatment
Jeong, J., & Kim, E. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189502 · Cited by 2
Morey, M. G., Illanad, G. H., & Rasool, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1754620 · Cited by 3
Albhaisi, S. A. M., & Sanyal, A. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00121-3 · Cited by 2
Delivery of Oligonucleotide Therapeutics for Macrophage Reprogramming in Inflammatory Diseases
Oza, D., & Amiji, M. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-84164-5_16 · Cited by 3
Inia, J. A., Morrison, M. C., van Koppen, A., Gart, E., Caspers, M. P. M., Menke, A. L., Worms, N., Kleemann, R., Verschuren, L., Jukema, J. W., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202500718r · Cited by 3
Frontiers and prospects of pharmacotherapy for non-alcoholic fatty liver disease
Zhang, S., & Wang, L. (2019) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v27.i2.73 · Cited by 2
Advances in the treatment of nonalcoholic steatohepatitis
Mukherjee, S. (2020) · World Journal of Pharmacology · doi:10.5497/wjp.v9.i1.1 · Cited by 2
Current Trends in Immuno-Oncology
Vanteddu, V. G., Bawari, S., & Patel, T. D. (2022) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/1871525720666220829142225 · Cited by 5
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape
Sohal, A., & Kowdley, K. V. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2330738 · Cited by 4
Li, M., Lu, C., Zhu, H., Kang, X., Wang, F., Shao, L., Lu, X., Chen, W., & Xia, X. (2019) · Europe PMC (PubMed Central) · Cited by 2
The Immense Impact of CCR5 Single-Nucleotide Polymorphisms (SNPs)Preprint
Hillman, T. (2020) · Preprints.org · doi:10.20944/preprints202010.0514.v1 · Cited by 1
Kushiro, K., Hirono, H., & Ohkoshi, S. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.03.011 · Cited by 2
Emerging Targets for the Treatment of Primary Sclerosing Cholangitis
Tatscher, E., Mady, S., & Fickert, P. (2025) · Seminars in Liver Disease · doi:10.1055/a-2601-9426 · Cited by 1
Лазебник, Л. Б., Туркина, С. В., & Golovanova, E. V. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-11-35 · Cited by 1
Ma, X., Lu, J., Zhong, T., Wang, X., Liu, X., Huo, W., & Chen, X. J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1863541 · Cited by 1
Zhu, L., & Wu, B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1899587 · Cited by 1
Drug Repurposing Patent Applications July–September 2016
Mucke, H. A. (2016) · Assay and Drug Development Technologies · doi:10.1089/adt.2016.29053.pq3 · Cited by 1
Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
Garbuzenko, D. V. (2022) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2021-31-5-16-24 · Cited by 1
“Двойной антагонист хемокиновых рецепторов CCR2/CCR5 ценикривирок в эксперименте на животных с моделью ФП способствовал значительному снижению рекрутирования моноцитов/макрофагов и уменьшению отложения коллагена [28].”
Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis
Iwaki, M., Yoneda, M., Wada, N., Otani, T., Kobayashi, T., Nogami, A., Saito, S., & Nakajima, A. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2328036 · Cited by 1
“Cenicriviroc, a CCR2/CCR5 antagonist, has demonstrated anti-fibrotic activity in animal models of hepatic and renal fibroses [91].”
BackgroundKaur, K. K., Allahbadia, G., & Singh, M. (2021) · Journal of Endocrinology Research · doi:10.30564/jer.v3i2.3580 · Cited by 2
“Simultaneous inhibition of CCR5 interferes with the migration, activation along with proliferation of the activated hepatic stellate cells ([71]).”
BackgroundChemokines at the Crossroad of Diabetes-Tuberculosis Synergy
Aravindhan, V., & Yuvaraj, S. (2022) · Biochemistry · doi:10.5772/intechopen.106598 · Cited by 1
AlAsfoor, S., Rohm, T. V., Bosch, A. J. T., Dervos, T., Calabrese, D., Matter, M. S., Weber, A., & Cavelti‐Weder, C. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/241224 · Cited by 1
Cytological Evaluation in Biomedical Research and Toxicity Studies
Poitout‐Belissent, F., Cora, M. C., & Wilcox, A. L. (2020) · doi:10.1002/9781119380559.ch66 · Cited by 1
Therapeutic Approaches for Nonalcoholic Steatohepatitis ( NASH )
Glatthar, R., & Arch, R. H. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc274 · Cited by 1
Zoubek, M. E. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210929mz · Cited by 1
Friedman, S. L. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch10 · Cited by 1
Self-citationVastrad, B. M., & Vastrad, C. M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.08.495272 · Cited by 1
Deasy, S., Amontree, M., Colon, Z. A., Thorland, E., Modi, K., Hummel, K., Blanco, I., Greco, G. A., Maguire‐Zeiss, K. A., & Conant, K. E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.09.687435 · Cited by 2
Lebeaupin, C., Donahue, K. L., Lal, S., Christensen, S. M., Asano, S., Wadsworth, M. H., Bound, K., De, S., McMahon, J., Schlerman, F., et al. (2025) · bioRxiv (preprint) · doi:10.64898/2025.12.17.694415
Drug Repurposing Patent Applications January–March 2016
Mucke, H. A. (2016) · Assay and Drug Development Technologies · doi:10.1089/adt.2016.29042.pq1 · Cited by 1
Overview of Clinical Treatment Trials for NASH
Konerman, M. A., & Harrison, S. A. (2017) · Current Hepatology Reports · doi:10.1007/s11901-017-0375-5
Antifibrotic Therapy for Liver Cirrhosis
Thủy, L. T. T., Hai, H., Hieu, V. N., Dat, N. Q., Hoang, D. V., & Kawada, N. (2019) · Springer eBooks · doi:10.1007/978-981-13-7979-6_15
Therapeutic Targeting of Hepatic Macrophages
Nijland, H., & Bansal, R. (2020) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-020-00008-7
“Studies have demonstrated that blocking of CCL2-mediated monocyte recruitment using a selective CCR2/CCR5 small-molecule inhibitor, cenicriviroc, ameliorates inflammation, and fibrosis in the liver and kidney fibrosis mouse models [35, 36].”
BackgroundManejo de la enfermedad hepática metabólica grasa
Lucena, A., Torrijo, Y. S., & Herrojo, J. A. (2020) · Revista Andaluza de Patología Digestiva · doi:10.37352/2020432.2
Anti-fibrotic Therapy for Chronic Liver Diseases Review
Naser, M., Naser, M. M., & Shehata, L. H. (2021) · International Journal of Progressive Sciences and Technologies · doi:10.52155/ijpsat.v29.2.3730
The Role of Myeloid-Derived Cells in the Progression of Liver Disease
(2020) · Frontiers research topics · doi:10.3389/978-2-88963-313-5
Metadata
- Authors
- Lefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., Richards, T., Yoneyama, H., Jenkins, H., Wolfgang, G., & Friedman, S. L.
- Affiliations
- Chelsea and Westminster Hospital (GB)
- Columbia University Irving Medical Center (US)
- University of Pennsylvania (US)
- AIDS Research Consortium of Atlanta (US)
- Icahn School of Medicine at Mount Sinai (US)
- Stelic (Japan) (JP)
- Charles River Laboratories (Canada) (CA)
- Corresponding author
- Friedman, Scott L.
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-06-27
- Volume
- 11
- Issue
- 6
- Pages
- e0158156
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4922569
- OpenAlex
- W2467384826
- Cited by
- 323
- References
- 51
- Citations by year
- 2026: 17 · 2025: 20 · 2024: 23 · 2023: 28 · 2022: 33 · 2021: 40 · 2020: 46 · 2019: 30 · 2018: 50 · 2017: 28 · 2016: 8
- FWCI
- 27.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institute of General Medical Sciences (T32GM007170)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- cenicriviroc, antifibrotic effect, liver fibrosis, renal fibrosis, nonalcoholic steatohepatitis, monocyte/macrophage recruitment, MCP-1, RANTES, hepatic stellate cell activation, collagen deposition, chemokine signaling, thioacetamide-induced liver fibrosis, diet-induced NASH
- MeSH terms
- Animals, Chemotaxis, Fibrosis, Imidazoles, Kidney Diseases, Macrophages, Male, Mice, Inbred C57BL, Monocytes, Sulfoxides, Rats, Sprague-Dawley, Mice, Rats, Receptors, CCR2, CCR5 Receptor Antagonists, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.